Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 2,828 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 2,828 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $35.04, for a total transaction of $99,093.12. Following the completion of the transaction, the insider owned 32,737 shares of the company’s stock, valued at $1,147,104.48. This represents a 7.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL traded down $0.71 during trading on Friday, reaching $33.79. The company had a trading volume of 347,753 shares, compared to its average volume of 435,825. The stock has a market capitalization of $1.04 billion, a PE ratio of -43.88 and a beta of 1.00. The stock has a 50-day moving average price of $34.35 and a two-hundred day moving average price of $28.33. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company has a current ratio of 5.28, a quick ratio of 5.12 and a debt-to-equity ratio of 0.01.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The business had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.76 million. As a group, sell-side analysts predict that Castle Biosciences, Inc. will post -0.83 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Assetmark Inc. boosted its position in Castle Biosciences by 9.3% during the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock valued at $142,000 after acquiring an additional 492 shares during the last quarter. Allworth Financial LP raised its position in shares of Castle Biosciences by 255.3% in the 3rd quarter. Allworth Financial LP now owns 938 shares of the company’s stock worth $33,000 after acquiring an additional 674 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Castle Biosciences by 15.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock worth $194,000 after acquiring an additional 747 shares in the last quarter. NFSG Corp acquired a new position in shares of Castle Biosciences in the 3rd quarter valued at about $36,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Castle Biosciences in the 2nd quarter valued at about $26,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. KeyCorp upped their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. BTIG Research boosted their target price on Castle Biosciences from $44.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Robert W. Baird upped their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Monday, November 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Castle Biosciences currently has an average rating of “Moderate Buy” and an average price target of $46.50.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.